MET and gastric cancer: MET overexpression (constituting 50%–60% of advanced GC), MET gene mutations (typically exon 14 skipping mutation) and amplification (constituting 4%–6% of advanced GC) are the most common forms of HGF/MET pathway alterations, yet their clinical implications are varied.13, 14, 15